Academic qualifications:

2002.1 –2006.10Ph.D. Temasek LifeSciences Laboratory, National University of Singapore

1993.9 – 1996.7M.Sc. Nankai University, China

1989.9 – 1993.7B.Sc.Nankai University, China

Present academic position:

2017.7 –Associate Professor, School of Biomedical Sciences, Faculty of Medicine,The Chinese University of Hong Kong

2021.8 –Deputy Chief of Developmental and Regenerative Biology Program,School of Biomedical Sciences, Faculty of Medicine,CUHK.

2018.2 –Deputy Director, CUHK-GIBH Joint Laboratory on Stem Cell and Regenerative Medicine

Previous academic positions held:

2010.11 – 2017.7Assistant Professor, School of Biomedical Sciences, Faculty of Medicine,The Chinese University of Hong Kong

2007.1 – 2010.11Postdoctoral Fellow & Research Associate, Genome Institute of Singapore, Singapore

1999.3 – 2006.12Junior Research Fellow, Temasek LifeSciences Laboratory, Singapore

1996.7 – 1999.2Tutor, Tianjin Normal University, China

Section A (5 representative publicationsin recent 5 years)

1.Chen L, Hong M, Luan C, Gao H, Ru G, Guo X, Zhang D, Zhang S, Li C, Wu J, Randolph PB, Sousa AA, Qu C, Zhu Y, Guan Y, Wang L, Liu M,Feng B,Song G, Liu DR & Li D. Adenine transversion editors enable precise, efficient A？T-to-C？G base editing in mammalian cells and embryos.Nat BiotechnolEpub. Jun15(2023).

2.He X*, Zhang Z*, Xue J, Wang Y, Zhang S, Wei J, Zhang C, Wang J, Urip BA, Ngan CC, Sun J, Li Y, Lu Z, Zhao H, Pei D, Li CK,Feng B^#. Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response.Nat Comm13:7275.(2022).

3.He X, Urip BA, Zhang Z, Ngan CC,Feng B#.Evolving AAV-delivered therapeutics towards ultimate cures.J Mol Med.99(5):593-617(2021).

4.WangJ, Zhang C,Feng B^#,The rapidly advancing Class 2 CRISPR-Cas technologies: a customizable toolbox for molecular manipulations.J Cell Mol Med. 24:3256-3270(2020)

5.Zhang C, He X, Kwok YK, Wang F, Xue Y, Zhao H, Suen KW, Wang CC, Ren J, Chen GG, Lai BS, Li J, Xia Y, Chan AM, Chan WY^#,Feng B^#,Homology-independent multiallelic disruption via CRISPR/Cas9-based knock-in yields distinct functional outcomes in human cells.BMC Biology16:151(2018).

Section B (5 representative publicationsbeyond recent 5 years)

1.He X, Tan C, Wang F, Wang Y, Zhou R, Cui D, You W, Zhao H, Ren J&Feng B^#.Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair,Nucleic Acids Res44(9):e85(2016).

2.Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H &Feng B^#,Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors,Nucleic Acids Res42(7):4375-90(2014).

3.Chia NY, Chan YS,Feng B*, Lu X, Orlov YL, Moreau D, Kumer P, Yang L, Jiang J, Lau MS, Huss M, Soh BS, Kraus P, Li P, Lufkin T, Lim B, Clarke ND, Bard F & Ng HH, A genome-wide RNAi screen reveals determinants of human ES cell identity.Nature468: 316–20(2010).(*Co-first authors)

4.Feng B,Ng JH, Heng JC, Ng HH., Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells,Cell Stem Cell4, 301-12(2009).

5.Feng B, Jian, J, Kraus P, Ng JH, Heng JC, Chan YS, Yaw LP, Zhang W, Loh YH, Han J, Vega VB, Cacheux-Rataboul V, Lim B, Lufkin T & Ng HH, Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb.Nat Cell Biol11:197-203(2009).